# A Study of IBI311 in Subjects With Active Thyroid Eye Disease

> **NCT05795621** · PHASE2,PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 115 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **BIOLOGICAL:** IBI311
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05795621
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-14
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2024-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05795621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05795621, "A Study of IBI311 in Subjects With Active Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05795621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*